Table 1 Demographic and clinical characteristics of the patients, by adverse event severity grading
Adverse events by severity grading (N = 51) | |||
|---|---|---|---|
Moderate-to-severe events (n = 26) | Mild events (n = 25) | P-value | |
Gender: Male, n (%) | 16 (61.5%) | 15 (60.0%) | 0.91 |
Age: mean ± SD, yrs | 34.1 ± 8.3 | 35.0 ± 10.2 | 0.71 |
Weight: mean ± SD, kg | 51.4 ± 10.3 | 53.9 ± 12.3 | 0.45 |
HIV co- infection, n (%) | 18 (69.2%) | 10 (40%) | 0.04 |
HAART, n (%) | 5 (19.2%) | 7 (28%) | 0.46 |
Duration (days) of therapy; median (IQR) | 183.5 (173–243) | 185 (175.5-212) | 0.81 |
Number of drugs in intensive phase regimen; median (IQR) | 5 (5–6) | 5 (5–6) | 0.61 |